MD-OncoMD-OncoMD-Onco2782-32022782-6171Publishing House ABV Press4510.17650/2782-3202-2022-2-3-47-54TREATMENT OF MALIGNANT BLOOD DISORDERS IN PATIENTS WITH COVID-19ЛЕЧЕНИЕ ЗЛОКАЧЕСТВЕННЫХ ЗАБОЛЕВАНИЙ СИСТЕМЫ КРОВИ У ПАЦИЕНТОВ С COVID-19Clinical observation of a 64-year-old female patient with plasma cell leukemia diagnosed during coronavirus infection COVID-19Клиническое наблюдение пациентки 64 лет с плазмоклеточным лейкозом, впервые выявленным на фоне новой коронавирусной инфекции COVID-19https://orcid.org/0000-0001-8443-8816RyabukhinaYu. E.РябухинаЮ. Е.
Russian Federation

Yulia E. Ryabukhina

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

Юлия Евгеньевна Рябухина

143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111

gemonk.yur@mail.ruhttps://orcid.org/0000-0002-6229-7300TimofeevaO. L.ТимофееваО. Л.
Russian Federation

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111

https://orcid.org/0000-0003-1564-424XZeynalovaP. A.ЗейналоваП. А.
Russian Federation

Department of Oncology I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081, 

Bld. 2, 8 Trubetskaya St., Moscow 119991

Кафедра онкологии ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет

143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111, 

119991 Москва, ул. Трубецкая, 8, стр. 2

https://orcid.org/0000-0002-2359-0547AbbasbeyliF. M.АббасбейлиФ. М.
Russian Federation

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111

AntonetsM. V.АнтонецМ. В.
Russian Federation

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111

https://orcid.org/0000-0002-9454-0002GruzdevV. E.ГруздевВ. Е.
Russian Federation

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111

https://orcid.org/0000-0002-4484-6716AnisimovM. A.АнисимовМ. А.
Russian Federation

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111

https://orcid.org/0000-0002-6395-5790AkhobekovA. A.АхобековА. А.
Russian Federation

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111

https://orcid.org/0000-0001-8509-0954KupryshinaN. A.КупрышинаН. А.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

Clinical Hospital “Lapino” of the “Mother and Child” Group of companiesКлинический госпиталь «Лапино» группы компаний «Мать и дитя»I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России131020222347541310202213102022Copyright ©; 2022, ABV-PressCopyright ©; 2022, АБВ-пресс2022ABV-PressАБВ-прессhttps://mdonco.abvpress.ru/jour/about/editorialPolicieshttps://mdonco.abvpress.ru/jour/article/view/45

Plasma cell leukemia (PCL) is a rare malignant plasma cell neoplasm with aggressive clinical progression, minimal response to therapy and unfavorable prognosis. Concomitant new coronavirus infection COVID-19 and its complications significantly worsen prognosis in patients with PCL. Currently, approaches to PCL therapy are not finalized, and regimens developed for multiple myeloma are used. In PCL, the most common clinical symptoms are renal failure and hypercalcinemia which are frequently observed in multiple myeloma. Therefore, use of proteasome inhibitor (bortezomib) with proven effectiveness in multiple myeloma, is justified. A clinical observation of a 64-year-old female patient who was hospitalized in poor physical condition with the new coronavirus infection COVID-19 is presented. During hospitalization, debut of PCL was suspected, and as soon as possible after diagnosis confirmation using vital indications, antitumor drug therapy was started with positive effect. 

Плазмоклеточный лейкоз (ПКЛ) – редкое злокачественное плазмоклеточное новообразование с агрессивным клиническим течением, минимальным ответом на проводимую терапию и неблагоприятным прогнозом. При развитии сопутствующей новой коронавирусной инфекции COVID-19 и осложнений ее течения прогноз у пациентов с ПКЛ значительно ухудшается. Подходы к терапии ПКЛ в настоящее время до конца не определены, и используются режимы, разработанные для лечения множественной миеломы. Поскольку при ПКЛ наиболее часто среди клинических симптомов встречаются почечная недостаточность и гиперкальциемия, которые нередко развиваются и при множественной миеломе, применение ингибитора протеасомы (бортезомиба), доказавшего свою эффективность во втором случае, является оправданным. Представлено клиническое наблюдение пациентки 64 лет, которая была госпитализирована в стационар в тяжелом соматическом состоянии с новой коронавирусной инфекцией COVID-19. При поступлении был заподозрен дебют развития ПКЛ, и в кратчайшие сроки после подтверждения диагноза по витальным показаниям начата противоопухолевая лекарственная терапия, проводимая с положительным эффектом.

plasma cell leukemiarenal failurebortezomibfast antitumor effectnew coronavirus infectionpulmonary thromboembolismплазмоклеточный лейкозпочечная недостаточностьбортезомиббыстрый противоопухолевый эффектновая коронавирусная инфекциятромбоэмболия легочной артерииUsmani S.Z., Nair B., Qu P. et al. Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols. Leukemia 2012;26(11):2398–405. DOI: 10.1038/leu.2012.107Gonsalves W.I., Rajkumar S.V., Go R.S. et al. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood 2014;124(6):907–12. DOI: 10.1182/blood-2014-03-565051Fernández de Larrea C., Kyle R.A., Durie B.G. et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia 2013;27(4):780–91. DOI: 10.1038/leu.2012.336Tiedemann R.E., Gonzalez-Paz N., Kyle R.A. et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia 2008;22(5):1044–52. DOI: 10.1038/leu.2008.4Van de Donk N.W., Lokhorst H.M., Anderson K.C., Richardson P.G. How I treat plasma cell leukemia. Blood 2012;120(12):2376–89. DOI: 10.1182/blood-2012-05-408682Gowin K., Skerget Sh., Keats J.J. et al. Plasma cell leukemia: a review of the molecular classification, diagnosis, and evidenced-based treatment. Leuk Res 2021;111:106687. DOI: 10.1016/j.leukres.2021.106687Jurczyszyn A., Radocha J., Davila J. et al. Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. Br J Haematol 2018;180(6):831–9. DOI: 10.1111/bjh.15092Jurczyszyn A., Castillo J.J., Avivi I. et al. Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. Leuk Lymphoma 2019;60(1):118–23. DOI: 10.1080/10428194.2018.1473574Chang H., Qi X., Yeung J. et al. Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia. Leuk Res 2009;33(2):259–62. DOI: 10.1016/j.leukres.2008.06.027Cazaubiel T., Buisson L., Maheo S. et al. The genomic and transcriptomic landscape of plasma cell leukemia. ASH Annual Meeting, 2020. Available at: https://ash.confex.com/ash/2020/webprogram/Paper139340.htmlMusto P., Simeon V., Martorelli M.C. et al. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia 2014;28(1):222–5. DOI: 10.1038/leu.2013.241Usmani S.Z., Hoering A., Ailawadhi S. et al. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. Lancet Haematol 2021;8(1):e45–e54. DOI: 10.1016/S2352-3026(20)30354-9Van De Donk N.V.D., van der Holt B., Schjesvold F.H. et al. Treatment of primary plasma cell leukemia with carfilzomib and lenalidomidebased therapy: results of the first interim analysis of the phase 2 EMN12/HOVON129 study. Blood 2019;134(Suppl 1):693. DOI: 10.1182/blood-2019-125120Gowda L., Shah M., Badar I. et al. Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. Bone Marrow Transplant 2019;54(7):1089–93. DOI: 10.1038/s41409-018-0392-1Mahindra A., Kalaycio M.E., Vela-Ojeda J. et al. Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. Leukemia 2012;26(5):1091–7. DOI: 10.1038/leu.2011.312Cha C.H., Park C.J., Huh J.R. et al. Significantly better prognosis for patients with primary plasma cell leukemia than for patients with secondary plasma cell leukemia. Acta Haematol 2007;118(3):178–82. DOI: 10.1159/000109470Katodritou E., Terpos E., Kelaidi C. et al. Treatment with bortezomibbased regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: analysis of the Greek myeloma study group. Am J Hematol 2014;89(2):145–50. DOI: 10.1002/ajh.23600Jimenez-Zepeda V.H., Reece D.E., Trudel S. et al. Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia. Leuk Lymphoma 2015;56(1):232–5. DOI: 10.3109/10428194.2014.893304Neben K., Lokhorst H.M., Jauch A. et al. Administration of bortezomib before and after autologous stem-cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood. 2012;119(4): 940–8. DOI: 10.1182/blood-2011-09-379164Avet-Loiseau H., Leleu X., Roussel M. et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010;28(30):4630–4. DOI: 10.1200/JCO.2010.28.3945Avet-Loiseau H., Leleu X., Roussel M. et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010;28(30):4630–4. DOI: 10.1200/JCO.2010.28.3945D’Arena G., Valentini C.G., Pietrantuono G. et al. Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party. Ann Oncol 2012;23(6):1499–502. DOI: 10.1093/annonc/mdr480Esparís-Ogando A., Alegre A., Aguado B. et al. Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer 2005;114(4):665–7. DOI: 10.1002/ijc.20793Esparís-Ogando A., Alegre A., Aguado B. et al. Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer 2005;114(4):665–7. DOI: 10.1002/ijc.20793Finnegan D.P., Kettle P., Drake M. et al. Bortezomib is effective in primary plasma cell leukemia. Leuk Lymphoma 2006;47(8):1670–3. DOI: 10.1080/10428190500520954Libby E., Candelaria-Quintana D., Moualla H. et al. Durable complete remission of primary plasma cell leukemia with the bortezomib plus melphalan and prednisone (VMP) regimen. Am J Hematol 2010;85(9):733–4. DOI: 10.1002/ajh.21790Grassinger J., Südhoff T., Andreesen R., Hennemann B. Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib. Ann Hematol 2006; 85(2):132–3. DOI: 10.1007/s00277-005-0027-7Wang H., Zhou H., Zhang Z. et al. Bortezomib-based regimens improve the outcome of patients with primary or secondary plasma cell leukemia: a retrospective cohort study. Turk J Haematol 2020;37(2):91–7. DOI: 10.4274/tjh.galenos.2019.2019.0254Musto P., Rossini F., Gay F. et al. Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer 2007;109(11):2285–90. DOI: 10.1002/cncr.22700Chudnova T.S., Baryakh E.A., Litvinenko M.S. et al. Chemotherapy of hematological malignancies in patients with COVID-19. Oncohematology 2022;17(2):107–20. (In Russ.). DOI: 10.17650/1818-8346-2022-17-2-107-120Чуднова Т.С., Барях Е.А., Литвиненко М.С. и др. Химиотерапевтическое лечение злокачественных заболеваний системы крови у пациентов с COVID-19. Онкогематология 2022;17(2):107–20. DOI: 10.17650/1818-8346-2022-17-2-107-120Passamonti F., Cattaneo C., Arcaini L. et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol 2020;7(10):e737–45. DOI: 10.1016/S2352-3026(20)30251-9Wang Q., Berger N.A., Xu R. Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 infection. JAMA Oncol 2021;7(2):220–7. DOI: 10.1001/jamaoncol.2020.6178Grivas P., Khaki A.R., Wise-Draper T.M. et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol 2021;32(6):787–800. DOI: 10.1016/j.annonc.2021.02.024Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020;18(4):844–7. DOI: 10.1111/jth.14768Lebedeva A.A., Kulikov A.N., Kovalchuk I.P. et al. Endothelial dysfunction and thrombotic events in patients with severe novel coronavirus infection COVID-19. Ucheniye zapiski SPbGMU im. akad. I.P. Pavlova = The Scientific Notes of the Pavlov University 2021;28(4):38–47. (In Russ.). DOI: 10.24884/1607-4181-2021-28-4-38-47Лебедева А.А., Куликов А.Н., Ковальчук Ю.П. и др. Эндотелиальная дисфункция и тромботические события у больных с тяжелым течением новой коронавирусной инфекции COVID-19. Ученые записки СПбГМУ им. акад. И.П. Павлова 2021;28(4):38–47. DOI: 10.24884/1607-4181-2021-28-4-38-47Klok F.A., Kruip M.J.H.A., van der Meer N.J.M. et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020;191:145–7. DOI: 10.1016/j.thromres.2020.04.013Miesbach W., Makris M. COVID-19: coagulopathy, risk of thrombosis, and the rationale for anticoagulation. Clin Appl Thromb Hemost 2020;26:1076029620938149. DOI: 10.1177/1076029620938149